Form 4: Verrica CEO Boosts Stake with Stock and Warrants

Verrica Pharmaceuticals CEO Jayson Rieger acquired 94,311 shares of common stock and 23,577 Series C warrants, increasing his direct beneficial ownership.

Summary

• Jayson Rieger, CEO and President of Verrica Pharmaceuticals Inc. (VRCA), acquired 94,311 shares of common stock and 23,577 Series C warrants.
• The transaction occurred on November 25, 2025, with the common stock purchased at $4.2425 per share as part of investment units.
• Each investment unit consisted of one share of Common Stock and a Series C warrant for one fourth of a share of common stock.
• The Series C warrants have an exercise price of $6.315 and expire on November 25, 2030.
• Following the transaction, direct beneficial ownership includes 182,593 shares of common stock and 23,577 Series C warrants.
• Indirect beneficial ownership includes 15 shares held by a child and 690 shares held across three separate trusts for immediate family members, for which the reporting person disclaims beneficial ownership.
• All reported security numbers have been adjusted to reflect a 1-for-10 reverse stock split effective July 24, 2025.
• The Series C Warrants include a limitation that prevents exercise if it would cause the aggregate beneficial ownership to exceed 9.99% of the Issuer's outstanding common stock.

Sentiment

Score: 8

Explanation: The significant insider buying by the CEO, including both common stock and warrants, indicates strong management confidence in the company's future, which is a highly positive signal for investors.

Positives

• The CEO's acquisition of a significant number of shares and warrants signals strong confidence in the company's future prospects.
• Insider buying at market prices often indicates management believes the stock is undervalued or expects positive developments.

Future Outlook

NA

Management Comments

• The acquisition of common stock and warrants by CEO Jayson Rieger demonstrates a strong vote of confidence in Verrica Pharmaceuticals' future performance and strategic direction.

Industry Context

NA

Stakeholder Impact

• Shareholders may view this insider buying as a positive indicator of future stock performance and management alignment with shareholder interests.
• Employees may perceive increased stability and confidence from leadership.

Key Dates

Recommendation

The substantial purchase of common stock and warrants by Verrica Pharmaceuticals' CEO, Jayson Rieger, signals strong insider confidence in the company's valuation and future prospects. Such a move by a key executive often precedes positive developments or reflects a belief that the stock is currently undervalued, making it an attractive 'buy' signal for seasoned investors.

Keywords

Verrica Pharmaceuticals, VRCA, Jayson Rieger, Insider Trading, Stock Purchase, Warrants, CEO, Beneficial Ownership